Omeros (NASDAQ:OMER) Stock Price Breaks Above Fifty Day Moving Average - Should You Sell?

Key Points

• Omeros shares broke above their 50-day moving average, reaching $19.28 and last trading at $18.95 on heavy volume. The stock’s 200-day moving average is $13.44, indicating notable recent momentum.
• Analyst sentiment is generally positive, with a consensus “Moderate Buy” rating and an average price target of $30.33, although Zacks downgraded the stock to “Hold.” Omeros also exceeded quarterly expectations, reporting $0.02 EPS versus a projected loss of $0.27 and revenue of $28.53 million.
• Insiders have been selling shares: company insiders sold 105,906 shares worth nearly $2.0 million over the past 90 days. Institutional investors own 48.79% of the stock, while the company continues developing therapies targeting complement and immune-system disorders.

Omeros Corporation (NASDAQ:OMER - Get Free Report)'s stock price passed above its 50-day moving average during trading on Thursday. The stock has a 50-day moving average of $18.52 and traded as high as $19.28. Omeros shares last traded at $18.95, with a volume of 3,627,702 shares traded.

Analyst Upgrades and Downgrades

Several analysts have issued reports on OMER shares. Cantor Fitzgerald restated an "overweight" rating and issued a $22.00 target price on shares of Omeros in a research note on Wednesday, October 14th. HC Wainwright reaffirmed a "buy" rating on shares of Omeros in a research report on Monday, July 27th. Zacks Research downgraded Omeros from a "strong-buy" rating to a "hold" rating in a research note on Monday, July 13th. Weiss Ratings raised Omeros from a "hold (c-)" rating to a "hold (c)" rating in a report on Thursday, October 8th. Finally, Wall Street Zen raised Omeros from a "hold" rating to a "buy" rating in a report on Saturday, August 15th. Three analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the stock. According to MarketBeat.com, Omeros has a consensus rating of "Moderate Buy" and an average price target of $30.33.

Omeros Stock Performance

The firm has a market capitalization of $1.37 billion, a PE ratio of 14.80 and a beta of 2.57. The business's 50 day moving average is $18.52 and its two-hundred day moving average is $13.44.

Omeros (NASDAQ:OMER - Get Free Report) last issued its earnings results on Wednesday, August 12th. The biopharmaceutical company reported $0.02 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.27) by $0.29. The business had revenue of $28.53 million for the quarter, compared to the consensus estimate of $12.69 million. As a group, equities research analysts predict that Omeros Corporation will post -0.37 EPS for the current year.

Insider Buying and Selling

In other news, VP Peter Cancelmo sold 25,000 shares of Omeros stock in a transaction on Monday, August 31st. The stock was sold at an average price of $18.54, for a total value of $463,500.00. Following the completion of the transaction, the vice president directly owned 200 shares in the company, valued at approximately $3,708. The trade was a 99.21% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Thomas Cable sold 15,000 shares of the business's stock in a transaction on Thursday, August 20th. The shares were sold at an average price of $18.45, for a total value of $276,750.00. Following the sale, the director owned 35,067 shares in the company, valued at approximately $646,986.15. The trade was a 29.96% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 105,906 shares of company stock valued at $1,989,705 in the last ninety days. 10.50% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the stock. Sterling Capital Management LLC grew its stake in Omeros by 75.3% during the third quarter. Sterling Capital Management LLC now owns 1,764 shares of the biopharmaceutical company's stock valued at $34,000 after acquiring an additional 758 shares in the last quarter. Assetmark Inc. bought a new stake in Omeros during the 1st quarter worth approximately $38,000. International Assets Investment Management LLC increased its holdings in Omeros by 16.0% during the 1st quarter. International Assets Investment Management LLC now owns 5,800 shares of the biopharmaceutical company's stock worth $61,000 after acquiring an additional 800 shares during the period. GK Wealth Management LLC bought a new stake in Omeros during the 3rd quarter worth approximately $65,000. Finally, Mirae Asset Global Investments Co. Ltd. purchased a new stake in Omeros in the 3rd quarter worth approximately $70,000. Hedge funds and other institutional investors own 48.79% of the company's stock.

Omeros Company Profile

Omeros Corporation NASDAQ: OMER is a biopharmaceutical company focused on discovering, developing and commercializing therapies for disorders involving the complement, immune and coagulation systems. The company has also developed a pipeline of investigational therapies aimed at treating serious diseases involving complement activation and immune-system dysfunction. The company is headquartered in Seattle, Washington, and was founded in 1994.

Its leading investigational programs have included narsoplimab, which targets the lectin pathway of the complement system, and OMS906, an antibody designed to inhibit MASP-3 and regulate the alternative pathway.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.